Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397293 · ClinicalTrials.gov registry record · Phase 1
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
A Phase 1 study, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00397293 is a Phase 1 study that has completed, run by Ascenta Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT00397293, a Phase 1 study, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
Interventions
- DRUG topotecan
- DRUG AT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397293
The ClinicalTrials.gov registry entry for NCT00397293 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which topotecan is the first listed.
NCT00397293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00397293 about?
NCT00397293 is a clinical study titled "Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer". This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
What is the current status of trial NCT00397293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00397293?
The interventions under investigation include: topotecan (DRUG), AT-101 (DRUG).
Who is sponsoring clinical trial NCT00397293?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.